Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2017-06-19 Major Shareholding Noti…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 1 page 101.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 under the Corporations Act 2001, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding interests, dates of changes, and associations related to voting securities. This type of filing is a notification about changes in major share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management report, but a regulatory notification about shareholding thresholds. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification.
2017-06-19 English
Becoming a substantial holder 2 pages 104.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder filed under the Corporations Act 2001 Section 671B. It details the substantial shareholding of Australian Land Pty Ltd in Phylogica Limited, including voting power, relevant interests, registered holders, consideration paid, and associates. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It fits the definition of Major Shareholding Notification (MRQ). The document length and content confirm it is the actual notification, not just an announcement or certification.
2017-06-19 English
Executive Director Remuneration 3 pages 98.9KB
Board/Management Information Classification · 100% confidence The document is an announcement detailing the material employment terms for newly appointed senior executives (Chief Executive Officer and Chief Scientific Officer) of Phylogica Limited. It includes terms of employment, salary, performance bonuses, and incentive options. There is no financial data, no report or presentation content, and no mention of voting results or regulatory filings. The content clearly relates to changes in senior management appointments and their contractual terms, which fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive about management appointments, not a brief announcement or a report publication notice.
2017-06-19 English
CEO and CSO Appointments 3 pages 94.5KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 19 June 2017 from Phylogica Limited. It announces the appointment of a new CEO and Chief Science Officer and the securing of $5 million in new funding. The content focuses on management changes and financing updates, including details about the executives' backgrounds and the company's strategic direction. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is not a full financial report, earnings release, or regulatory filing. It is primarily an announcement of management appointments and capital raising activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it covers both the funding secured and the executive appointments related to the company's financing and strategic development.
2017-06-18 English
Change of Director's Interest Notice 2 pages 57.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings and interests of a company director, including number of shares held before and after the change, nature of interest, and transactions. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives. The document is about a director's share transactions, not a general regulatory filing or announcement. Therefore, the correct classification is DIRS.
2017-06-18 English
Change in substantial holding 2 pages 262.2KB
Regulatory Filings
2017-06-18 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.